We recently compiled a list of 11 Best Future Stocks to Buy Now. Crinetics Pharmaceuticals, Inc. stands fifth on our list.
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) stands fifth on our list among the best future growth stocks to buy now. It is a clinical-stage biopharmaceutical company focused on developing oral, small-molecule therapies for rare endocrine diseases and tumors. Its lead candidate, PALSONIFY (paltusotine), is an investigational once-daily oral somatostatin receptor type 2 (SST2) agonist being developed for acromegaly.
At the July 2025 ENDO Annual Meeting, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) presented long-term data from the open-label extensions of its PATHFNDR-1 and PATHFNDR-2 Phase 3 trials, showing that PALSONIFY maintained durable IGF-1 control, reduced symptom burden, and had a consistent safety profile. These findings strengthen its case as a next-generation oral alternative to current injectable therapies, which are the standard of care for acromegaly.
The company is now approaching a major inflection point, with a PDUFA date set for late 2025, potentially making PALSONIFY the first oral treatment approved for acromegaly. This would represent a significant shift in disease management and convenience for patients.
A scientist in a laboratory looking into a microscope, researching advances in biopharmaceuticals for central nervous system disorders.
Beyond PALSONIFY, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) is advancing other pipeline programs, including Atumelnant, aimed at treating congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, as well as several early-stage endocrine disorder therapies. The corporation also expanded its workforce in July 2025, granting equity awards to 46 new employees to support future growth.
While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.